DexCom, Inc. (DXCM) Shares Sold by Stephens Inc. AR

Stephens Inc. AR decreased its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 48.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,990 shares of the medical device company’s stock after selling 3,795 shares during the period. Stephens Inc. AR’s holdings in DexCom were worth $338,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Livforsakringsbolaget Skandia Omsesidigt bought a new stake in DexCom during the first quarter valued at approximately $136,000. IFP Advisors Inc raised its stake in DexCom by 9.3% in the first quarter. IFP Advisors Inc now owns 1,863 shares of the medical device company’s stock valued at $158,000 after buying an additional 159 shares during the period. Mn Services Vermogensbeheer B.V. raised its stake in DexCom by 3.8% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 2,254 shares of the medical device company’s stock valued at $179,000 after buying an additional 83 shares during the period. Daiwa Securities Group Inc. raised its stake in DexCom by 475.0% in the first quarter. Daiwa Securities Group Inc. now owns 2,300 shares of the medical device company’s stock valued at $195,000 after buying an additional 1,900 shares during the period. Finally, Accredited Investors Inc. bought a new stake in DexCom during the first quarter valued at approximately $201,000.

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

DexCom, Inc. (DXCM) traded up 3.64% on Monday, hitting $71.50. 720,193 shares of the company’s stock traded hands. DexCom, Inc. has a one year low of $57.68 and a one year high of $96.38. The stock has a 50-day moving average of $71.61 and a 200-day moving average of $73.78. The stock’s market cap is $6.18 billion.

DexCom (NASDAQ:DXCM) last announced its earnings results on Tuesday, May 2nd. The medical device company reported ($0.49) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.55) by $0.06. DexCom had a negative net margin of 14.70% and a negative return on equity of 32.94%. The business had revenue of $142.30 million for the quarter, compared to analyst estimates of $143.94 million. On average, equities analysts forecast that DexCom, Inc. will post ($0.70) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “DexCom, Inc. (DXCM) Shares Sold by Stephens Inc. AR” was originally published by Mideast Time and is owned by of Mideast Time. If you are accessing this report on another website, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.mideasttime.com/dexcom-inc-dxcm-shares-sold-by-stephens-inc-ar/1773668.html.

DXCM has been the subject of several analyst reports. B. Riley restated a “buy” rating and issued a $94.00 price objective on shares of DexCom in a research note on Monday, February 13th. Oppenheimer Holdings, Inc. restated a “buy” rating on shares of DexCom in a research note on Thursday, April 13th. Northcoast Research restated a “buy” rating on shares of DexCom in a research note on Wednesday, March 1st. Jefferies Group LLC upped their price objective on DexCom from $80.00 to $91.00 and gave the stock a “buy” rating in a research note on Wednesday, March 1st. Finally, Canaccord Genuity reduced their price objective on DexCom from $95.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, May 3rd. Four analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $90.44.

In other news, SVP Jacob Steven Leach sold 21,317 shares of DexCom stock in a transaction dated Tuesday, March 14th. The shares were sold at an average price of $77.63, for a total value of $1,654,838.71. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Andrew K. Balo sold 3,200 shares of DexCom stock in a transaction dated Monday, April 10th. The shares were sold at an average price of $78.19, for a total transaction of $250,208.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 82,912 shares of company stock worth $6,226,140. Company insiders own 1.70% of the company’s stock.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:DXCM”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.